Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
Benjamin G. Vincent(University of North Carolina at Chapel Hill), Jonathan S. Serody(University of North Carolina at Chapel Hill), Hyman B. Muss(University of North Carolina at Chapel Hill), Jeffrey A. Frelinger, Carey K. Anders(Duke University), Elizabeth Claire Dees(University of North Carolina at Chapel Hill), Lisa M. Bixby(University of North Carolina at Chapel Hill), Yara A. Park(University of North Carolina at Chapel Hill), Shannon Reisdorf(Segeberger Kliniken), Lisa A. Carey(University of North Carolina at Chapel Hill), Danielle M. File, Hendrik W. van Deventer(University of North Carolina at Chapel Hill), Sonia J. Laurie(University of North Carolina at Chapel Hill), Dominic T. Moore(University of North Carolina at Chapel Hill), Joseph G. Ibrahim(University of North Carolina at Chapel Hill), Frances A. Collichio(Institute for Tourism), Edward J. Collins(University of North Carolina at Chapel Hill), Karen P. McKinnon(Segeberger Kliniken)
Cited by 19
Related Papers
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991